Trial Profile
Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs MB 101 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Brain cancer; Glioblastoma; Glioma
- Focus Adverse reactions
- 05 Oct 2023 Planned End Date changed from 18 Sep 2023 to 24 Aug 2024.
- 05 Oct 2023 Planned primary completion date changed from 18 Sep 2023 to 24 Aug 2024.
- 22 Sep 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 18 Sep 2020 to 18 Oct 2020.